Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
American food And administer the medication on Wednesday consent A new obesity pill called Foundayo. The pill is taken once daily and is manufactured by the pharmaceutical company Eli Lilly, which also makes the popular weight loss injection Zepbound.
Foundayo is a type of medicine known as a GLP-1a category that includes competitors Ozempic and Wegovy. These medications mimic a hormone that occurs naturally in the body that regulates blood sugar, slows digestion, and signals the brain that you are full.
It is now the second GLP-1 weight loss pill on the market. In December, Novo Nordisk Obtained FDA approval For its tablet form of Wegovy. The company’s original version of Wegovy is a weekly injection. While Wijovi pills should be taken on an empty stomach in the morning, Lilly says Fundayo can be taken at any time of the day without food or water restrictions.
As demand for injectable GLP-1 drugs rose, so did pharmaceutical companies The race to develop weight loss pillswhich may be preferable for some patients and could expand the GLP-1s market. Pills are also easier to manufacture than injectable drugs, which may help maintain continuous access for patients. GLP-1 drugs They were in severe shortage From late 2022 until early 2025 because demand has exceeded manufacturing capacity.
“Beyond supply and affordability, one of the biggest barriers to drug adoption has been that some patients don’t want to take the shot,” says Ken Custer, Eli Lilly’s executive vice president. “It may be because it’s a needle, but it may also be that for them, the injection signals that their condition is more serious than they feel at that point. For patients looking to start their weight management journey, the pill may be an easier place for them to start.”
Like injectable GLP-1s, Foundayo starts at a low dose and is gradually increased to reduce the nausea, vomiting, and diarrhea that can come with these medications.
In a clinical trial, individuals who took the highest dose of Fundayo over 18 months lost an average of 27 pounds, or 12.4 percent of their body weight over 18 months. Those who took the placebo lost only 2 pounds, or less than 1% of their body weight, during the same time. Lilly’s tirzepatide, the active ingredient in the injectable drugs Mounjaro and Zepbound, has shown weight reduction of more than 20 percent.
For Novo Nordisk’s Wegovy pill, study participants achieved an average weight loss of 13.6 percent over 16 months. There have been no direct trials to compare the effectiveness of Foundayo and Wegovy pills.
Eli Lilly did Conduct a study To find out what happens when people switch from injectable GLP-1 to Foundayo, they found that it helped people maintain most of their weight loss. Those who switched to Wegovy’s injectable pills regained an average difference of 2 pounds, while those who switched to Foundayo from Zepbound gained an average of 11 pounds. The active ingredient in Foundayo, orforglipron, is also being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis, knee pain, and other conditions.
Foundayo is available now via LillyDirect’s direct-to-consumer platform, with shipping beginning April 6. Eli Lilly says Foundayo will be more widely available via retail pharmacies and telehealth providers in the U.S. shortly after. The pill is included in the November 2025 deal to be offered through the TrumpRx platform.
The FDA said in its announcement on Wednesday that it reviewed Fundayo cream in just 50 days as part of a plan New pilot program It aims to accelerate approvals of medicines that align with national health priorities. Approval of new drugs usually takes between six and ten months.